Getting real-world evidence to the sponsor before the deadline, not after

Real‑world evidence only counts if it reaches the decision‑maker before the window closes.

When a non-interventional breast cancer study needed its interim analysis 10 days ahead of a tight plan, the TFS HealthScience oncology team did not add people or push back on the ask. They changed how the team worked.

In this case study you will discover:

  • Why the solution had nothing to do with headcount
  • How the team structure made the difference
  • What the outcome looked like across every deliverable

Download the case study to see how the team delivered.

Connect with Us

Contact us today to discover how TFS can be your strategic CRO partner in clinical development.

Let's Talk

Latest Oncology Resources

The new endpoints reshaping oncology trial designWebinars

The new endpoints reshaping oncology trial design

The endpoint and eligibility shifts reshaping oncology trial design in 2026. Watch the full replay or download the slides.
ASCO Oncology
10 oncology trial readouts to watch for at ASCO 2026Article

10 oncology trial readouts to watch for at ASCO 2026

Biomarker-defined populations. Rare cancers. Multi-country designs. As ASCO 2026 approaches, TFS HealthScience outlines the ten oncology trials that matter most and what they mean for sponsors planning their next programme.
Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to KnowArticle

Insights from ASCO 2025: Oncology Clinical Trial Trends CROs and Sponsors Need to Know

Explore key takeaways from ASCO 2025, from ctDNA and AI to novel biologics and inclusive trials. Learn how to stay ahead in oncology research.